Results 141 to 150 of about 8,380,026 (270)

Engineered immunostimulatory H2O2‐producing microreactors driven by yeast as localized living cancer therapeutics

BMEMat, EarlyView.
Engineered yeast microreactors that produce H2O2 within tumors enable selective cancer cell killing while releasing immunostimulatory components, effectively suppressing local tumor growth and activating systemic antitumor immunity, with further efficacy enhanced by anti‐PD‐1 therapy and transarterial embolization.
Wenqian He, Chunjie Wang, Minming Chen, Weihao Yang, Bin Yu, Yuhang Hu, Hengze Ding, Yifan Yan, Zhijuan Yang, Liangzhu Feng   +9 more
wiley   +1 more source

Non-surgical Management of Locally Advanced Basal Cell Carcinoma of the Upper Extremity With Vismodegib. [PDF]

Cureus, 2022
Swisher AR, Landau MJ, Davila AB, Davila AA, Zagaynov C, Bobbitt CA, Leong DS, Chang AY, Chang WT.   +8 more
europepmc   +1 more source

Antimicrobial Peptides and Peptidomimetics in Foods – A Synthetic Foray

ChemFoodChem, EarlyView.
This Review discusses AMPs in foods and their syntheses. It espouses facile methods to make them accessible and suggests their utility in the mitigation and eradication of the burgeoning maladies of antimicrobial and multidrug resistance (AMR and MDR).
Josephat U. Izunobi, Adejoke D. Osinubi, Abosede A. Badeji   +2 more
wiley   +1 more source

Turning Bonding Into Function: The Emerging Role of the Bioactive Selenium─Metal Motif in Toxicology and Medicinal Chemistry

Chemistry – A European Journal, EarlyView.
Balancing Act: Se─M bond serving as the fulcrum of the balance scale to compare the different weight of toxicity and therapeutic effects in biological environment. ABSTRACT The synthesis and characterization of organo‐selenium compounds have attracted considerable interest for decades, driven by the search for efficient catalysts and bioinspired ...
Matteo Filippi, Alessandro Rubbi, Pablo A. Nogara, Giovanni Ribaudo, Vito Lippolis, João B. T. Rocha, Laura Orian   +6 more
wiley   +1 more source

Long-term efficacy of telemedicine for patients with locally advanced basal cell carcinoma during COVID-19 pandemic. [PDF]

Dermatol Ther, 2022
Villani A, Potestio L, Fabbrocini G, di Vico F, Costa C, Scalvenzi M.   +5 more
europepmc   +1 more source

Exposure–Response Analysis of Enfortumab Vedotin Plus Pembrolizumab as First‐Line Therapy for Locally Advanced or Metastatic Urothelial Cancer

Clinical Pharmacology &Therapeutics, EarlyView.
Enfortumab vedotin is a nectin‐4‐directed antibody–drug conjugate currently approved in combination with pembrolizumab for the first‐line treatment of locally advanced or metastatic urothelial cancer. Here we describe the exposure–response relationship between enfortumab vedotin exposures and efficacy/safety endpoints in patients who received ≥1 dose ...
Vaishali L. Chudasama, Helen Kastrissios, Hossam Kadry, Daping Zhang, Salaheldin Hamed, Srinivasu Poondru, Souvik Bhattacharya, Russ Wada, Amit Garg, Yen Lin Chia   +9 more
wiley   +1 more source

Frequency and Genomic Aspects of Intrinsic Resistance to Vismodegib in Locally Advanced Basal Cell Carcinoma. [PDF]

Clin Cancer Res, 2022
Yurchenko AA, Pop OT, Ighilahriz M, Padioleau I, Rajabi F, Sharpe HJ, Poulalhon N, Dreno B, Khammari A, Delord M, Alberti A, Soufir N, Battistella M, Mourah S, Bouquet F, Savina A, Besse A, Mendez-Lopez M, Grange F, Monestier S, Mortier L, Meyer N, Dutriaux C, Robert C, Saiag P, Herms F, Lambert J, de Sauvage FJ, Dumaz N, Flatz L, Basset-Seguin N, Nikolaev SI.   +31 more
europepmc   +1 more source

Toward Fit‐for‐Purpose Data for Drug Assessment in Non‐small Cell Lung Cancer: A Core Dataset

Clinical Pharmacology &Therapeutics, EarlyView.
Considering the high unmet medical need in people with non‐small cell lung cancer (NSCLC), the drug assessment for targeted therapies often rely on small populations and single‐arm trials, challenging the evaluation by regulatory authorities, health technology assessment bodies (HTAb), and clinicians.
Geeske F. Grit, Maaike van Dartel, Laura Rodwell, Hanneke van der Woude, Cornelis Boersma, Peter G. M. Mol, Doranne Hilarius   +6 more
wiley   +1 more source

The prognostic and therapeutic significance of biological molecular markers in human anorectal carcinomas treated with 5'fluorouracil chemoradiation. [PDF]

, 2005
Advances in tumour biology have led to studies of new biological markers, which may predict treatment response and clinical outcome independently of standard clinicopathological variables.
Mawdsley, S.K.V.
core  

Exposure‐Response Analyses of Datopotamab Deruxtecan (Dato‐DXd), a TROP2‐Directed Antibody‐Drug Conjugate, in Advanced Non‐small Cell Lung Cancer

Clinical Pharmacology &Therapeutics, EarlyView.
Exposure‐response analyses supported a favorable benefit‐risk profile of Dato‐DXd at 6 mg/kg Q3W in patients with advanced nonsquamous NSCLC. Datopotamab deruxtecan (Dato‐DXd) is a trophoblast cell‐surface antigen‐2 (TROP2)‐directed antibody‐drug conjugate (ADC) that has demonstrated clinical activity in patients with NSCLC who have received prior ...
Ying Hong, Anna M. Mc Laughlin, Yuzhuo Pan, Sofia Friberg Hietala, Sophie Peigné, Michael Chargualaf, Zoey Tang, Diansong Zhou, Naoyuki Tajima, Malaz Abutarif, Tushar Garimella   +10 more
wiley   +1 more source